Matches in SemOpenAlex for { <https://semopenalex.org/work/W4309048061> ?p ?o ?g. }
Showing items 1 to 80 of
80
with 100 items per page.
- W4309048061 endingPage "266" @default.
- W4309048061 startingPage "258" @default.
- W4309048061 abstract "Aim Although fibrates were developed as lipid-lowering drugs, their efficacy against liver dysfunction in patients with cholestatic liver diseases, such as primary biliary cholangitis, primary sclerosing cholangitis, and fatty liver disease, has also been reported. Although fibrates act on some peroxisome proliferator-activated receptors (PPARs), pemafibrate is a novel selective PPAR-α modulator. The present study aimed to evaluate the safety and efficacy of switching from bezafibrate to pemafibrate in patients with chronic liver disease. Methods We analyzed 58 patients with chronic liver disease who switched from bezafibrate to pemafibrate because of minor adverse effects and/or incomplete response. Results This study included 41 patients with cholestatic liver disease and 17 patients with non-alcoholic fatty liver disease. Reasons for switching to pemafibrate were renal function decline in 31 patients, hemoglobin decline in 17 patients, creatine kinase (CK) elevation in 11 patients, incomplete response of liver dysfunction in 39 patients, and incomplete response of hyperlipidemia in 13 patients. After 3 months, although no significant change in CK was seen, hemoglobin and estimated glomerular filtration rate were significantly increased, and creatinine was significantly decreased. Significant decreases in hepatobiliary enzymes were seen in patients with cholestatic liver diseases, but not in patients with non-alcoholic fatty liver disease. No significant changes in serum lipids were observed. No patients discontinued pemafibrate due to adverse events. Conclusions Switching to pemafibrate could improve adverse effects due to bezafibrate, and appeared effective against liver dysfunction in cholestatic liver disease patients with incomplete response to bezafibrate." @default.
- W4309048061 created "2022-11-21" @default.
- W4309048061 creator A5021225592 @default.
- W4309048061 creator A5029428902 @default.
- W4309048061 date "2022-11-29" @default.
- W4309048061 modified "2023-09-27" @default.
- W4309048061 title "Safety and efficacy of switching to pemafibrate from bezafibrate in patients with chronic liver disease" @default.
- W4309048061 cites W1726014254 @default.
- W4309048061 cites W2054851194 @default.
- W4309048061 cites W2116137858 @default.
- W4309048061 cites W2170684362 @default.
- W4309048061 cites W2280192011 @default.
- W4309048061 cites W2605729742 @default.
- W4309048061 cites W2765263832 @default.
- W4309048061 cites W2789204053 @default.
- W4309048061 cites W2807617765 @default.
- W4309048061 cites W2886703787 @default.
- W4309048061 cites W2943905083 @default.
- W4309048061 cites W3047965158 @default.
- W4309048061 cites W3087664331 @default.
- W4309048061 cites W3135550722 @default.
- W4309048061 cites W3186664775 @default.
- W4309048061 cites W3198111024 @default.
- W4309048061 cites W3201123873 @default.
- W4309048061 cites W3209074017 @default.
- W4309048061 cites W4206905543 @default.
- W4309048061 doi "https://doi.org/10.1111/hepr.13859" @default.
- W4309048061 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36378065" @default.
- W4309048061 hasPublicationYear "2022" @default.
- W4309048061 type Work @default.
- W4309048061 citedByCount "2" @default.
- W4309048061 countsByYear W43090480612023 @default.
- W4309048061 crossrefType "journal-article" @default.
- W4309048061 hasAuthorship W4309048061A5021225592 @default.
- W4309048061 hasAuthorship W4309048061A5029428902 @default.
- W4309048061 hasConcept C126322002 @default.
- W4309048061 hasConcept C197934379 @default.
- W4309048061 hasConcept C2776362216 @default.
- W4309048061 hasConcept C2777075537 @default.
- W4309048061 hasConcept C2777214474 @default.
- W4309048061 hasConcept C2778772119 @default.
- W4309048061 hasConcept C2779102576 @default.
- W4309048061 hasConcept C2779134260 @default.
- W4309048061 hasConcept C2992208098 @default.
- W4309048061 hasConcept C512861765 @default.
- W4309048061 hasConcept C71924100 @default.
- W4309048061 hasConcept C90924648 @default.
- W4309048061 hasConceptScore W4309048061C126322002 @default.
- W4309048061 hasConceptScore W4309048061C197934379 @default.
- W4309048061 hasConceptScore W4309048061C2776362216 @default.
- W4309048061 hasConceptScore W4309048061C2777075537 @default.
- W4309048061 hasConceptScore W4309048061C2777214474 @default.
- W4309048061 hasConceptScore W4309048061C2778772119 @default.
- W4309048061 hasConceptScore W4309048061C2779102576 @default.
- W4309048061 hasConceptScore W4309048061C2779134260 @default.
- W4309048061 hasConceptScore W4309048061C2992208098 @default.
- W4309048061 hasConceptScore W4309048061C512861765 @default.
- W4309048061 hasConceptScore W4309048061C71924100 @default.
- W4309048061 hasConceptScore W4309048061C90924648 @default.
- W4309048061 hasIssue "3" @default.
- W4309048061 hasLocation W43090480611 @default.
- W4309048061 hasLocation W43090480612 @default.
- W4309048061 hasOpenAccess W4309048061 @default.
- W4309048061 hasPrimaryLocation W43090480611 @default.
- W4309048061 hasRelatedWork W1980774155 @default.
- W4309048061 hasRelatedWork W1986152242 @default.
- W4309048061 hasRelatedWork W2106326535 @default.
- W4309048061 hasRelatedWork W2140912948 @default.
- W4309048061 hasRelatedWork W2354581436 @default.
- W4309048061 hasRelatedWork W2369560021 @default.
- W4309048061 hasRelatedWork W2970146669 @default.
- W4309048061 hasRelatedWork W3216746909 @default.
- W4309048061 hasRelatedWork W4238004163 @default.
- W4309048061 hasRelatedWork W4309048061 @default.
- W4309048061 hasVolume "53" @default.
- W4309048061 isParatext "false" @default.
- W4309048061 isRetracted "false" @default.
- W4309048061 workType "article" @default.